18,19-dihydroetorphine (dihydroetorphine)

Subscribe to Selected New Research on 18,19-dihydroetorphine

9 relevant articles (0 outcomes, 3 trials/studies) found for this Bio-Agent

Description: RN given refers to (5alpha,7alpha(R))-isomer; structure given in first source

Also Known As:

dihydroetorphine; dihydroetorphine hydrochloride

Bio-Agent Context: Research Results

Related Diseases

1.	Pain (Aches) 07/06/2001 - "These results indicate that topical application of dihydroetorphine has a tolerance and dependence liability when there is no pain, and therefore, it should be used only for pain relief." 09/11/1998 - "The remarkable potency, maximal efficacy and duration of action of these compounds, particularly dihydroetorphine, suggests that these compounds may warrant further examination as potential therapeutic treatments for neuropathic pain states." 01/01/1991 - "One hundred and three patients with moderate and severe cancer pain were given a sublingual analgesic agent--dihydroetorphine hydrochloride (DHE)" 01/01/1991 - "Dihydroetorphine hydrochloride for moderate and severe cancer pain]" 09/11/1998 - "Anti-allodynic actions of intravenous opioids in the nerve injured rat: potential utility of heroin and dihydroetorphine against neuropathic pain." Get all the results and reference details, order at left...
2.	Neuroblastoma 05/01/1998 - "The present study was undertaken to compare the neurotoxic effects of three etorphine-like opiates (etorphine, dihydroetorphine, and another derivative of oripavine) and heroin with their ability to activate opiate receptors in human neuroblastoma cell line SK-N-SH as well as in two other neuronal cell lines" Get all the results and reference details, order at left...
3.	Opioid-Related Disorders (Opiate Addiction) 02/14/1994 - "These in vitro studies may clarify the mechanisms underlying the potent analgesic effects of etorphine and dihydroetorphine in vivo and to guide the use of these and other excitatory opioid receptor antagonists in attenuating development of opiate dependence/addiction." Get all the results and reference details, order at left...
4.	Weight Loss (Weight Reduction) 07/06/2001 - "Naloxone-precipitated weight loss was observed after 24-h infusion of dihydroetorphine but not after the tape application in non-inflamed rats" 03/01/1995 - "Composite scores of naloxone (4 mg.kg-1, ip) precipitated abstinence syndromes were calculated and the magnitude of weight loss was determined in chronic morphine (Mor)- or dihydroetorphine (DHE)-treated rats" Get all the results and reference details, order at left...
5.	Labor Pain 06/01/1995 - "Influence of dihydroetorphine hydrochloride and tramadol on labor pain and umbilical blood gas]" Get all the results and reference details, order at left...
11 Diseases and 9 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Opioid Receptors (Opioid Receptor)
2.	Etorphine (M99)
3.	Heroin (Diamorphine)
4.	Morphine (MS Contin)
5.	Fentanyl (Sublimaze)
6.	oripavine
7.	Naloxone (Narcan)
8.	Tramadol
9.	Interleukin-2 (IL2)
10.	Formaldehyde (Formol)
12 Drugs and Important Bio-Agents and 7 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Ligation
2.	Analgesia
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>